Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Aviva in £300m share buyback as FY profits rise 9%

(Sharecast News) - UK insurance giant Aviva on Thursday unveiled a £300m share buyback and better-than-expected 9% rise in full-year earnings on a strong increase in general insurance premiums. Operating profit increase to £1.47bn, compared with forecasts of £1.43bn. General Insurance premiums were up 13% to £10.8bn.

Aviva added that it was setting a new target for operating profit of £2bn by 2026. The dividend was lifted 8% to 33.4p a share with renewed guidance of growth in the cash cost by mid-single digits.

The private health insurance business also increased sales by 41% as people looked to avoid long waits on National Health Service lists.

Chief executive Amanda Blanc dismissed market speculation about a takeover for the company as "largely market chatter".

There were reports last year that Allianz, Intact Financial and Tyrg were interested in buying Aviva, pushing up the share price. More recently it has been reportedly in the sights of Italian insurer Generali.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

Hikma boosts injectables business with Xellia assets acquisition
(Sharecast News) - Hikma Pharmaceuticals said on Monday that it has agreed to buy parts of Xellia Pharmaceuticals, a Copenhagen-based specialty company focusing on providing anti-infective treatments and other critical care therapies, for up to $185m.
Ascential on track to hit targets this year
(Sharecast News) - Publishing, events and B2B consultancy group Ascential has said that trading is in line with expectations for the full year, helped by strong growth in marketing and fintech operations.
AstraZeneca's Imfinzi gets US approval for endometrial cancer patients
(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.
British Land CFO to join Kingfisher
(Sharecast News) - B&Q owner Kingfisher said it had appointed British Land chief financial officer Bhavesh Mistry to the same role at the home improvement company.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.